Final Guidance Clarifies Distribution Requirements For MedGuides
Final policy on distribution of Medication Guides and inclusion in Risk Evaluation and Mitigation Strategies makes clear what FDA considers a material change.
You may also be interested in...
FDA said a Medication Guide need not be encompassed within NPS Pharma’s proposed Risk Evaluation and Mitigation Strategy for teduglutide due to the extensive interactions between short bowel syndrome patients and their health care providers and the inclusion of other patient-directed materials.
FDA continues to mull reducing patient leaflets to a one-page document – and continues to tell pharmacists that having to print the current version is not a burden.
Not surprisingly, FDA is imposing REMS less frequently in the fourth year of its new post-marketing authorities. But mandatory trial requirements appear to be rising, as is the use of the most burdensome type of REMS.